Pharmaceutical and diagnostics giant Roche has recently integrated a suite of AI algorithms into its enterprise digital pathology software.
The company has collaborated with South Korean firm Deep Bio to power the navify digital pathology platform with the prostate cancer analysis AI solution, DeepDx Prostate. The AI technology provides pathologists with gland-level Gleason grading, measurements of tissue and tumour, and diagnosis support.
DeepDx Prostate has been widely tested in the United States, analysing over 700,000 core needle biopsies. It also has regulatory approval in Europe.
Singapore-based Qritive also announced the integration of its digital pathology AI solutions into Roche’s navify.
It includes AI modules for detecting colon, prostate, breast, and gastric cancers in whole slide images. These solutions also provide tumour grading.
Meanwhile, mental health startup Wundrsight from India has received $400,000 in seed funding from a round led by Inflection Point Ventures.
Founded in 2022, the company currently offers six virtual reality-based digital therapeutics products for treating mental, behavioural, and neurocognitive health conditions – including substance use disorders, OCD, anxiety, phobia, and autism.
Based on a press statement, the startup will use its fresh funds to secure more partnerships across India and develop more VR-based mental health solutions. Operating currently in three major cities, Wundrsight said its VR solutions are being used in over five hospitals and have already been used in treating around 1,000 patients.